317 related articles for article (PubMed ID: 19667989)
1. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
5. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition reduces donor-specific antibody levels.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Brown E; Tevar A; Woodle ES
Transplant Proc; 2009; 41(1):105-7. PubMed ID: 19249489
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitor therapy for antibody-mediated rejection.
Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
[TBL] [Abstract][Full Text] [Related]
10. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.
Wahrmann M; Haidinger M; Körmöczi GF; Weichhart T; Säemann MD; Geyeregger R; Kikić Z; Prikoszovich T; Drach J; Böhmig GA
Transplantation; 2010 Jun; 89(11):1385-90. PubMed ID: 20335829
[TBL] [Abstract][Full Text] [Related]
11. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
12. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Pavlakis M
Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
[TBL] [Abstract][Full Text] [Related]
13. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.
Wahrmann M; Haidinger M; Drach J; Geyeregger R; Kikić Z; Raab R; Säemann MD; Böhmig GA
Clin Transpl; 2009; ():415-20. PubMed ID: 20524307
[TBL] [Abstract][Full Text] [Related]
15. The state of therapy for removal of alloantibody producing plasma cells in transplantation.
Everly MJ; Terasaki PI
Semin Immunol; 2012 Apr; 24(2):143-7. PubMed ID: 22153981
[TBL] [Abstract][Full Text] [Related]
16. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J
Clin Transpl; 2009; ():351-8. PubMed ID: 20527073
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2010; ():429-36. PubMed ID: 21696060
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib for acute humoral rejection in two repeat transplant recipients.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports.
Sberro-Soussan R; Zuber J; Suberbielle-Boissel C; Legendre C
Clin Transpl; 2009; ():433-8. PubMed ID: 20524311
[TBL] [Abstract][Full Text] [Related]
20. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
[No Abstract] [Full Text] [Related]
[Next] [New Search]
